- Home
- GRND vs ZLAB Comparison
GRND vs ZLAB Comparison
Compare GRND & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRND
- ZLAB
- Stock Information
- Founded
- GRND 2009
- ZLAB 2013
- Country
- GRND United States
- ZLAB China
- Employees
- GRND N/A
- ZLAB N/A
- Industry
- GRND Computer Software: Prepackaged Software
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- GRND Technology
- ZLAB Health Care
- Exchange
- GRND Nasdaq
- ZLAB Nasdaq
- Market Cap
- GRND 2.1B
- ZLAB 1.8B
- IPO Year
- GRND N/A
- ZLAB 2017
- Fundamental
- Price
- GRND $13.65
- ZLAB $31.24
- Analyst Decision
- GRND Strong Buy
- ZLAB Strong Buy
- Analyst Count
- GRND 3
- ZLAB 4
- Target Price
- GRND $15.33
- ZLAB $52.50
- AVG Volume (30 Days)
- GRND 464.9K
- ZLAB 976.3K
- Earning Date
- GRND 11-07-2024
- ZLAB 11-12-2024
- Dividend Yield
- GRND N/A
- ZLAB N/A
- EPS Growth
- GRND N/A
- ZLAB N/A
- EPS
- GRND N/A
- ZLAB N/A
- Revenue
- GRND $300,034,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- GRND $30.64
- ZLAB $48.34
- Revenue Next Year
- GRND $21.70
- ZLAB $47.12
- P/E Ratio
- GRND N/A
- ZLAB N/A
- Revenue Growth
- GRND 34.98
- ZLAB 28.16
- 52 Week Low
- GRND $5.71
- ZLAB $13.48
- 52 Week High
- GRND $13.90
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- GRND 63.17
- ZLAB 70.41
- Support Level
- GRND $13.06
- ZLAB $31.52
- Resistance Level
- GRND $13.90
- ZLAB $36.60
- Average True Range (ATR)
- GRND 0.42
- ZLAB 1.36
- MACD
- GRND 0.06
- ZLAB 0.34
- Stochastic Oscillator
- GRND 80.54
- ZLAB 58.60
About GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.